Sant Boi De Llobregat

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

Researchers are evaluating whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas. This study compares sclerotherapy to expectant management to determine which approach better helps manage symptoms and quality of life impacts associated with this common form of endometriosis. Participants are randomly assigned to either receive ultrasound-guided alcohol sclerotherapy involving puncture and alcohol treatment of the cysts or to be managed expectantly with standard pain management if needed. The sclerotherapy procedure involves a 15-minute application of absolute ethanol followed by a wash. Both groups will be followed for six months, with assessments at baseline and 6 months post-treatment. During the study, participants will complete quality of life and pain assessments using standardized tools, provide blood and urine samples for biomarker analysis, and undergo ovarian reserve evaluations. Researchers will monitor adverse events, cyst recurrence, fertility outcomes, and healthcare costs. Pregnancy outcomes will be followed for an average of two years. The main outcome is quality of life measured at baseline and 6 months.

Researchers are evaluating the effectiveness of the PIPPEP digital platform in improving treatment adherence and clinical outcomes for young adults aged 18 to 40 who are receiving early intervention for psychosis. This trial aims to assess whether adding the PIPPEP platform to usual care helps patients stick to their psychosocial and pharmacological treatments better. The study also looks at the platforms cost-effectiveness, its reach among patients, and effects on symptoms, medication side effects, social stigma, risk, comorbid symptoms, and social functioning. Participants are randomly assigned to one of two groups. One group receives usual care plus access to the PIPPEP platform, which provides educational content, regular self-assessment questionnaires, two-way messaging with the care team, and gamified rewards. The control group receives usual care without the platform. Questionnaires are completed at the start, six months, and twelve months, with some completed weekly. The intervention program includes multidisciplinary care with psychiatric, nursing, social work, and psychological support for up to five years. Participants will be monitored throughout the study with assessments at baseline, six months, and twelve months. These include adherence to treatment, costs, symptom impact, medication side effects, cognitive insight, substance use, anxiety and depression, social stigma, quality of life, and overall functioning. Data from questionnaires completed via the platform are securely stored in medical records. The study aims to improve engagement and prognosis by combining digital tools with personalized follow-up in early psychosis care.

Researchers are evaluating the effects of combining water aerobics with Metacognitive Training MCT for people diagnosed with psychosis. The study aims to compare this combined approach to each intervention alone, focusing on improvements in clinical, cognitive, metacognitive, psychosocial aspects, motor coordination, and physical health. It also investigates changes in SP1 and SP4 biomarker levels related to the treatments received. The study is designed to see if combining these interventions enhances benefits in symptoms, cognition, and social functioning. Participants are divided into three groups one receiving water aerobics, another receiving MCT, and a third group receiving both interventions. Water aerobics involves a weekly one-hour session led by a specialized trainer focusing on motor coordination, strength, and cardiovascular fitness for three months. MCT consists of weekly one-hour sessions with a psychologist targeting common cognitive biases in psychosis, covering topics like attributional style, jumping to conclusions, theory of mind, emotion recognition, memory, and empathy. Those in the combined group attend both types of sessions weekly for three months. During the study, participants will be assessed at the start and after three months using various clinical and cognitive tests, questionnaires, and physical health measurements. These include scales for cognitive insight, cognitive biases, stress, psychosis symptoms, depression, self-esteem, personal attributions, social cognition, functioning, disability, stigma, quality of life, awareness of mental disorder, and physical indicators like heart rate, blood pressure, weight, body measurements, glucose, cholesterol, and sleep quality. Researchers will monitor changes in these areas along with biomarker levels to evaluate the interventions effects over the study period.

Researchers are evaluating an eHealth platform called ePro-Schools designed to promote physical activity, healthy eating, and reduce sedentary behavior among adolescents from socially disadvantaged backgrounds in Central Catalonia. The study aims to address gaps in public health policies by co-designing the platform with adolescents, school staff, and policymakers. This randomized controlled trial will assess the programs effectiveness, cost-effectiveness, and implementation in six secondary schools with around 1000 adolescent participants. The intervention includes two digital platforms an Intervention Platform containing interactive modules for students and physical education teachers, and an Information Platform with educational resources for students, teachers, and families. The program will be delivered during one school year 202526 through web-based access. Schools are randomized into an intervention group receiving full access to the platform and a control group receiving only basic health-related information, with the control group gaining access to the full platform after the trial. Participants will be evaluated at baseline, post-intervention, and nine months after post-intervention for physical activity levels, sedentary behavior, and dietary habits, which are the primary outcomes. Secondary outcomes include physical fitness, water consumption, quality of life, depressive symptoms, social isolation, and sleep quality. The study also involves surveys, questionnaires, interviews, and focus groups to monitor adoption, acceptability, and feasibility. The total participation covers the school year and follow-up period with continuous engagement and data collection.

Fibromyalgia is a common syndrome that currently has no cure and results in significant healthcare and societal costs. Researchers are investigating the effectiveness, physiological effects, and cost-utility of a self-guided digital intervention called STANZA-Spain, which is based on Acceptance and Commitment Therapy ACT for adults diagnosed with fibromyalgia. This trial is a six-month, three-arm randomized controlled study recruiting 360 adults who meet the 2016 American College of Rheumatology criteria for fibromyalgia. Participants will be randomly assigned to one of three groups Treatment as usual TAU plus the STANZA digital ACT app, TAU plus a digital symptom tracking app called FibroST, or TAU alone. The STANZA app offers 41 structured ACT lessons designed to be completed in 8 weeks, followed by 4 weeks of maintenance. FibroST provides daily symptom tracking and educational materials without psychotherapy. TAU involves usual care by general practitioners and specialists, including consultations, advice, and medications. Throughout the study, participants will be assessed at baseline, after treatment, and at 6 months follow-up. Assessments include functional impairment using the Fibromyalgia Impact Questionnaire Revised FIQR, patient impressions of change, measures of depression, anxiety, stress, cognitive impairment, and pain catastrophizing. Immune-inflammatory biomarkers will be collected at baseline and post-treatment in a subset of participants. Researchers will also conduct a qualitative analysis to better understand user experiences with the STANZA app. The total study duration for participants is six months.